BMO Capital initiated coverage of Nurix Therapeutics (NRIX) with an Outperform rating and $35 price target The firm believes the company is poised to deliver significant growth with its protein degradation platform, noting that its BTK degrader, NX-5948, is demonstrating that degradation of the BTK protein can lead to clinical responses in patients that have progressed on prior lines of targeted therapies. The firm views Nurix as “well-positioned for long-term growth” given the size of the current BTK market and the opportunity to expand into new indications, the analyst tells investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics announces PRIME designation for NX-5948 from EMA
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Nurix Therapeutics initiated with a Buy at UBS
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
- Nurix Therapeutics Appoints Anil Kapur to Board
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
